Imugene’s (ASX: IMU) onCARlytics and Artemis® T cells combination abstract presented at ASGCT event - Kalkine Media

Highlights

• The abstract details the combination of IMU's onCARlytics technology and Eureka Therapeutics’ Artemis® CD19 T cells
• The ASGCT meeting will be held later this month and will be attended by cell therapy professionals
• Imugene's platform technologies channel and focus the body’s immune system against tumours

Imugene Limited (ASX: IMU) -- which is developing novel immunotherapies to treat and eradicate tumours -- has informed that the company's onCARlytics technology will be presented this month as part of an abstract at ASGCT. ASGCT is short for the American Society of Gene and Cell Therapy. The Annual Meeting event is attended by cell therapy professionals with discussions on new scientific developments in the field. The event will be held from 16^th May in California, the US.

Imugene’s abstract at the event investigates the onCARlytics and Artemis® CD19 T cells combination in the most primary type of liver cancer.

Image source: Pixabay.com; Data source: Company update

More

Imugene's abstract -- ‘Effective combination immunotherapy using onCARlytics and Artemis® CD19 T cells against hepatocellular carcinoma’ -- is related to one of the most common cancers and notes how the combination could show highly encouraging in-vivo anti-tumour responses in a human xenograft HepG2 liver cancer model. The abstract also states that the strategy can also be used in otherwise immune target-less tumours like hepatocellular carcinoma, with potential to be used in a wide range of solid cancers.

IMU states that even though hepatocellular carcinoma has curative treatment options, alongside existing systemic therapies, the CD19 targeting CAR T therapy has demonstrated encouraging clinical results. The onCARlytics and Artemis® T cell platform combination presents an effective immunotherapy approach.

Notably, the ASGCT event would be held for the 26th time this year in May, and it will be visited by professionals from the industry to discuss new research & development and emerging technologies. The venue for the meeting is the Los Angeles Convention Center.

About Imugene

The clinical-stage immuno-oncology company, which is listed on the ASX, is developing immunotherapies that can have the ability to activate the immune system of patients and cure and eliminate tumours. Imugene has a number of immunotherapy B-cell vaccine candidates, alongside an oncolytic virotherapy. These aim to treat a range of cancers in combination with standard of care medicines and emerging immunotherapies like CAR T.

The company's ASX-listed shares traded at a price of AU$0.122 (market cap of over AU$802 million) midday on 3 May 2023.